Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses

Pandemic and epidemic outbreaks of respiratory viruses are a challenge for public health and social care system worldwide, leading to high mortality and morbidity among the human populations. In light of the limited efficacy of current vaccines and antiviral drugs against respiratory viral infection...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-09, Vol.24 (18), p.13888
Main Authors: Chianese, Annalisa, Zannella, Carla, Monti, Alessandra, Doti, Nunzianna, Sanna, Giuseppina, Manzin, Aldo, De Filippis, Anna, Galdiero, Massimiliano
Format: Article
Language:English
Subjects:
Animals
antimicrobial peptide
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Anura
coronavirus
Coronavirus 229E, Human
Coronaviruses
COVID-19
COVID-19 vaccines
Coxsackievirus infections
Cytotoxicity
Disease transmission
Drug resistance
Drug therapy
Herpes viruses
Humans
Infections
Influenza
Influenza A Virus, H1N1 Subtype
Influenza viruses
inhibitory peptide
Measles
Pandemics
Peptides
Public health
Rabies
Respiratory diseases
Respiratory syncytial virus
respiratory viruses
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Swine flu
Vaccines
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pandemic and epidemic outbreaks of respiratory viruses are a challenge for public health and social care system worldwide, leading to high mortality and morbidity among the human populations. In light of the limited efficacy of current vaccines and antiviral drugs against respiratory viral infections and the emergence and re-emergence of new viruses, novel broad-spectrum antiviral drugs are needed for the prevention and treatment of these infections. Antimicrobial peptides with an antiviral effect, also known as AVPs, have already been reported as potent inhibitors of viral infections by affecting different stages of the virus lifecycle. In the present study, we analyzed the activity of the AVP Hylin-a1, secreted by the frog , against a wide range of respiratory viruses, including the coronaviruses HCoV-229E and SARS-CoV-2, measles virus, human parainfluenza virus type 3, and influenza virus H1N1. We report a significant inhibitory effect on infectivity in all the enveloped viruses, whereas there was a lack of activity against the naked coxsackievirus B3. Considering the enormous therapeutic potential of Hylin-a1, further experiments are required to elucidate its mechanism of action and to increase its stability by modifying the native sequence.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241813888